$Gorilla Technology (GRRR.US)$
If it maintains at least 25.45, breaking through the swing high of 28.29 would lead to 30.04/31.79/32.88🚀.
If it breaks through the swing high of 34.85, then 36.38/37.47🚀.

$Gorilla Technology (GRRR.US)$
Good evening nya~n.
The entire market is experiencing a decline.
Tonight there are many remote communications and emails from American, and four devices, including smartphones, are fully operational.It becomes frustrating to deal with the naked king.
Currently, if it falls below 78.6% of 23.71, it could go down to 23.04/22.62.
If it falls below the swing low of 22.24, the likelihood of breaking down to 21.31 (21.25)/20.35 (20.30) increases.
As long as it maintains and exceeds 78.6% of 23.71, the target for upward movement is 30.57/33.19/34.81.🚀🚀
It is hoped to hold above 25.67 if possible.
See you again, bye-bye.

$Direxion Daily Semiconductor Bull 3x Shares ETF (SOXL.US)$
Good evening nya~n.
It is likely to decline.
Currently, it is a decline in wave 5 rally, so there is a possibility of breaking down to 103.83/99.77/99.13/97.24.
I hope it does not fall below the 38.2% retracement of 99.13.
It is expected that there is a high possibility of an oversold bounce at either 103.83/99.77/99.13/97.24.
Even if it falls, it is highly likely to form an upward trend setup of 1-2 due to an oversold bounce, but it is uncertain how the announcement of tariffs by Trump on the 2nd will affect it.
It seems like this week will continue to have perplexing days.
But let's keep a positive attitude and do our best.

$Tesla (TSLA.US)$
Good evening nya~n.
Fell below the Resistance of 256 to 249.82
Will there be a bounce due to oversellingIs it losing the Resistance at 248?
The current situation is whether it can maintain 248.60, but if it falls below, then 246.39/241.71/238.60/237.63/234.72.Below that is 226/205.
Currently, it is Wave 3 from a 1-2 setup, but if it drops below 249.82, it will complete Wave 4 and enter a decline in Wave 5.
If it rises above 249.82, even if it breaks through the 50% retracement at 256.73, it won't invalidate the Wave rally, and the hurdle is high as it requires holding and breaking through 264.59 after surpassing 261.
The first-quarter shipping and production figures are scheduled to be announced on Wednesday, the 2nd, so it depends on the numbers.It also depends on Trump's tariff policy on the 2nd.
See you again, bye-bye.

[Market Overview] Stocks: The Nikkei average at the close suffered its largest drop of the year, falling below 0.03 million 6000 yen due to concerns over the USA economy.March 31, 2025, 3:38 PM GMT+9.
The Nikkei average at the close suffered its largest drop of the year, falling below 0.03 million 6000 yen due to concerns over the USA economy.
In the Tokyo stock market, the Nikkei average closed at 35,617.56 yen, down 1,502.77 yen from the previous trading day, marking a significant three-day decline. Concerns over USA tariff policies and the economy weighed heavily, pushing it below the key level of 36,000 yen at the end of trading. The decline was the largest this year. The drop in major stocks contributing to the Index ETF and technology stocks became a burden on the market. Additionally, the appreciation of the yen against the dollar in the foreign exchange market was also unwelcome.
[Market Overview] Interest Rates: Treasury Futures rise significantly, with long-term interest rates at 1.485%, the lowest in three and a half weeks, due to risk-off sentiment.
Treasury Futures rise significantly, with long-term interest rates at 1.485%, the lowest in three and a half weeks, due to risk-off sentiment.
Treasury Futures for June rose by 63 cents to 138.40 yen, finishing significantly higher. The yield on newly issued 10-year Treasury bonds (long-term interest rate) fell by 6.0 basis points (bp) to 1.4...

Angle: The market is bracing for Trump's tariff announcement, with the possibility that uncertainty may not be resolved.March 31, 2025, at 12:11 PM GMT+9
The date of April 2, when President Trump is expected to announce details about reciprocal tariffs and sector-specific tariffs, is approaching. However, very few investors expect that the uncertainty that has cast a large shadow over the financial markets this year will be completely dispelled by that day.
Due to concerns surrounding Trump's tariff policy, the S&P 500 temporarily fell by 10% compared to its peak in March. Since the beginning of 2025, it has dropped about 3%, marking the largest decline rate in the first quarter since 2022, in three years.
Mark Marek, Chief Investment Officer (CIO) of Siebert Financial Corp, stated, "I am an eternal Bullish, but I believe that from now until the first week of April and the beginning of the Earnings Reports season, stock prices are more likely to decline than rise."
On April 2, it is expected that actual tariff rates, as well as which countries and sectors will be targeted and whether the opposing country will retaliate, will cause stock prices to fluctuate dramatically.
However, the Chief Investment Strategist at State Street Global Advisors, M...

Eli Lilly and Co's Alzheimer’s drug, the European Medicines Agency has recommended rejection of approval.March 31, 2025, 15:06 JST
Pointed out that there is no benefit that outweighs the significant risk of intracranial hemorrhage for 'Kesanra.'
Lilly plans to seek a re-examination - expressed 'disappointment' at the recommendation.
Regarding the early Alzheimer's treatment drug "Kesanra" by the American pharmaceutical giant Eli Lilly and Co, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended against approval for sale. It states that the benefits do not outweigh the significant risk of intracranial hemorrhage.
Lilly had been aiming to obtain approval for Kesanra (generic name Donanemab) for the treatment of early Alzheimer's disease. The final decision will be made by the European Commission, the EU's executive body. Lilly expressed disappointment in the recommendation and indicated plans to seek a re-examination.
The company is competing with Eisai and its partner Biogen in the global market for Alzheimer's treatment drugs, and this recommendation is a significant blow. According to Bloomberg Intelligence (BI), the revenue of pharmaceuticals in this field is expected to reach 13 billion dollars (approximately 1.94 trillion yen) by 2030, compared to approximately 250 million dollars last year.